Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover-Reference-Cited by-同舟云学术

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

Published:2001-03-01 Issue:3 Volume:49 Page:298-303
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

De La Fuente-Fernández Raúl,Lu Jian-Qiang,Sossi Vesna,Jivan Salma,Schulzer Michael,Holden James E.,Lee Chong S.,Ruth Thomas J.,Calne Donald B.,Stoessl A. Jon

Funder

Canadian Institutes for Health Research

Pacific Parkinson's Research Institute (Vancouver, Canada)

British Columbia Health Research Foundation

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference35 articles.

1. Motor response complications and the function of striatal efferent systems;Chase;Neurology,1993

2. The response to levodopa in Parkinson's disease: imposing pharmacological law and order;Nutt;Ann Neurol,1996

3. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms: 1;Fabbrini;Ann Neurol,1988

4. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms;Bravi;Ann Neurol,1994

Cited by 188 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parkinson’s Disease;International Encyclopedia of Public Health;2025

2. “Advanced” Parkinson's disease: A review;Parkinsonism & Related Disorders;2024-06

3. In Vitro Human Monoamine Oxidase Inhibition and Human Dopamine D4 Receptor Antagonist Effect of Natural Flavonoids for Neuroprotection;International Journal of Molecular Sciences;2023-11-01

4. Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions;Journal of Clinical Medicine;2023-06-30

5. Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia;Neuropharmacology;2023-03